Comparative proteomics analysis of polo-like kinase 1 inhibition by BI 6727 (Volasertib) in human melanoma

被引：0
|
作者：
Cholewa, B. D. [1 ]
Pellitteri-Hahn, M. C. [1 ]
Scarlett, C. O. [1 ]
Ahmad, N. [1 ,2 ]
机构：
[1] Univ Wisconsin, Madison, WI USA
[2] William S Middleton VA Med Ctr, Madison, WI USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2014年 / 134卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
192
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [1] Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo
    Cholewa, Brian D.
    Ndiaye, Mary A.
    Huang, Wei
    Liu, Xiaoqi
    Ahmad, Nihal
    CANCER LETTERS, 2017, 385 : 179 - 187
  • [2] Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAFV600E Mutant Melanoma Cells
    Cholewa, Brian D.
    Pellitteri-Hahn, Molly C.
    Scarlett, Cameron O.
    Ahmad, Nihal
    JOURNAL OF PROTEOME RESEARCH, 2014, 13 (11) : 5041 - 5050
  • [3] Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Maris, John M.
    Reynolds, C. Patrick
    Kang, Min H.
    Carol, Hernan
    Lock, Richard
    Billups, Catherine A.
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 158 - 164
  • [4] Pediatric Preclinical Testing Program (PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK) inhibitor
    Smith, Malcolm
    Keir, Stephen
    Maris, John
    Kolb, Anders
    Reynolds, Patrick
    Kang, Min
    Carol, Hernan
    Lock, Richard
    Gorlick, Richard
    Kurmasheva, Raushan
    Billups, Catherine
    Houghton, Peter
    CANCER RESEARCH, 2012, 72
  • [5] Combination of Radiation and Polo-like Kinase 1 Inhibition with BI 6727 in Tumor Model A431
    Krause, M.
    Eicheler, W.
    Kummer, B.
    Doerfler, A.
    Yaromina, A.
    Baumann, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 : 53 - 53
  • [6] Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1
    Wu, Chung-Pu
    Hsieh, Chia-Hung
    Hsiao, Sung-Han
    Luo, Shi-Yu
    Su, Ching-Ya
    Li, Yan-Qing
    Huang, Yang-Hui
    Huang, Chiun-Wei
    Hsu, Sheng-Chieh
    MOLECULAR PHARMACEUTICS, 2015, 12 (11) : 3885 - 3895
  • [7] Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells
    Pezuk, Julia Alejandra
    Brassesco, Maria Sol
    Manzini Ramos, Priscila Maria
    Scrideli, Carlos Alberto
    Tone, Luiz Gonzaga
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (09) : 1278 - 1291
  • [8] A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
    Lin, C-C
    Su, W-C
    Yen, C-J
    Hsu, C-H
    Su, W-P
    Yeh, K-H
    Lu, Y-S
    Cheng, A-L
    Huang, D. C-L
    Fritsch, H.
    Voss, F.
    Taube, T.
    Yang, J. C-H
    BRITISH JOURNAL OF CANCER, 2014, 110 (10) : 2434 - 2440
  • [9] A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
    C-C Lin
    W-C Su
    C-J Yen
    C-H Hsu
    W-P Su
    K-H Yeh
    Y-S Lu
    A-L Cheng
    D C-L Huang
    H Fritsch
    F Voss
    T Taube
    J C-H Yang
    British Journal of Cancer, 2014, 110 : 2434 - 2440
  • [10] A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
    Schoffski, Patrick
    Awada, Ahmad
    Dumez, Herlinde
    Gil, Thierry
    Bartholomeus, Sylvie
    Wolter, Pascal
    Taton, Martine
    Fritsch, Holger
    Glomb, Patricia
    Munzert, Gerd
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (02) : 179 - 186
12345